Status note Phase 1 complete; IND cleared with Phase 2 clinical protocol. Development paused post-merger while exploring monetization of clinical assets; resumed development contingent on funding.
Status note Phase 1b safety/tolerability/PK study complete (topline Q1 2022). Development paused; monetization under review.
PUR1900
Phase 1 · ActiveModality: dry powder for inhalation
Indications
Allergic bronchopulmonary aspergillosis (ABPA) in asthma and cystic fibrosis(Phase 1)
Status note Prior clinical study terminated July 2020. Development paused post-merger; monetization under review.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.